Skip to main content
OpenTrials
Completed

NCT Number: NCT03699579

Pharmaco-Economic Study of Treatment Options in Patients With Advanced RCC

This is a retrospective cohort study aiming to collect data on patients' characteristics, resource utilization, adverse events management and calculate costs attributed to current treatments of advance RCC patients who have received at least one prior VEGF-targeted therapy in Taiwan from National Health Insurance (NHI) perspective.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Renal Cell Carcinoma Metastatic Adenocarcinoma Carcinoma Carcinoma, Renal Cell Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Kidney Diseases Kidney Neoplasms Male Urogenital Diseases Neoplasms Neoplasms by Histologic Type Neoplasms by Site Neoplasms, Glandular and Epithelial Renal Cell Carcinoma Urogenital Diseases Urogenital Neoplasms Urologic Diseases Urologic Neoplasms

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

National Taiwan University Hospital, Taipei, Taiwan

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients with confirmed diagnosis of clear-cell renal cell carcinoma
  • Patients with evidence of metastatic disease
  • Patients who have received at least one previous VEGFR-targeted therapy, i.e sunitinib, pazopanib or sorafenib
  • Patients who received care at the selected medical centers, utilizing the National Health Insurance (NHI) reimbursed system at the time of the disease

Exclusion criteria

  • Patients enrolled in any clinical trial involving anti-cancer therapy
  • Pregnant woman

Treatment and study plan

Primary outcomes

  1. Medication usage

    Time frame: From start point for 2.5 months

  2. Treatment's duration

    Time frame: From start point for 2.5 months

Secondary outcomes

  1. Cost of medication used

    Time frame: From start point for 2.5 months

  2. Costs of adverse event management

    Time frame: From start point for 2.5 months

    (total calculated costs attributed to Adverse Effects (AEs) management according to the attached list of adverse events

  3. Frequency of health resource usage

    Time frame: From start point for 2.5 months

    Outpatient department visits, CT scan, blood test number and types

  4. Cost of health resource usage

    Time frame: From start point for 2.5 months

    Outpatient department visits, CT scan, blood test number and types

Sponsors and collaborators

Lead sponsor

Ipsen

Industry

Registry information

Official study title

Patients Characteristics, Treatment Utilization, Costs and Outcomes in Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC) Who Received at Least One Prior Vascular Endothelial Growth Factor (VEGF)-Targeted Therapy in Taiwan

Important dates

Study start
2019
Primary completion
2019
Study completion
2019
First posted
Oct 9, 2018
Registry last updated
Aug 28, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.